553 related articles for article (PubMed ID: 31595657)
1. Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials.
Mannucci E; Dicembrini I; Nreu B; Monami M
Diabetes Obes Metab; 2020 Feb; 22(2):203-211. PubMed ID: 31595657
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
[TBL] [Abstract][Full Text] [Related]
3. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
[TBL] [Abstract][Full Text] [Related]
4. Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.
Nreu B; Dicembrini I; Tinti F; Sesti G; Mannucci E; Monami M
Nutr Metab Cardiovasc Dis; 2020 Jun; 30(7):1106-1114. PubMed ID: 32448716
[TBL] [Abstract][Full Text] [Related]
5. Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta-analysis of randomized controlled trials with external adjudication of events.
Mannucci E; Gallo M; Giaccari A; Candido R; Pintaudi B; Targher G; Monami M;
Diabetes Obes Metab; 2023 Feb; 25(2):444-453. PubMed ID: 36205446
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Kristensen SL; Rørth R; Jhund PS; Docherty KF; Sattar N; Preiss D; Køber L; Petrie MC; McMurray JJV
Lancet Diabetes Endocrinol; 2019 Oct; 7(10):776-785. PubMed ID: 31422062
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
Sattar N; Lee MMY; Kristensen SL; Branch KRH; Del Prato S; Khurmi NS; Lam CSP; Lopes RD; McMurray JJV; Pratley RE; Rosenstock J; Gerstein HC
Lancet Diabetes Endocrinol; 2021 Oct; 9(10):653-662. PubMed ID: 34425083
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis.
Nguyen BN; Nguyen L; Mital S; Bugden S; Nguyen HV
Diabetes Obes Metab; 2023 Jun; 25(6):1614-1623. PubMed ID: 36751968
[TBL] [Abstract][Full Text] [Related]
9. Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials.
Monami M; Zannoni S; Pala L; Silverii A; Andreozzi F; Sesti G; Mannucci E
Int J Cardiol; 2017 Aug; 240():414-421. PubMed ID: 28501352
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis.
Zhang X; Shao F; Zhu L; Ze Y; Zhu D; Bi Y
BMC Pharmacol Toxicol; 2018 Sep; 19(1):58. PubMed ID: 30223891
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
Bethel MA; Patel RA; Merrill P; Lokhnygina Y; Buse JB; Mentz RJ; Pagidipati NJ; Chan JC; Gustavson SM; Iqbal N; Maggioni AP; Öhman P; Poulter NR; Ramachandran A; Zinman B; Hernandez AF; Holman RR;
Lancet Diabetes Endocrinol; 2018 Feb; 6(2):105-113. PubMed ID: 29221659
[TBL] [Abstract][Full Text] [Related]
12. Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with glucagon-like peptide-1 receptor agonists (GLP-1RAs): A pooled analysis of type 2 diabetes trials.
Diallo A; Carlos-Bolumbu M; Renard PE; Galtier F
Diabetes Obes Metab; 2023 Jan; 25(1):166-176. PubMed ID: 36057779
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of Glucagon-Like Peptide-1 Receptor Agonists to Reduce Adverse Cardiovascular Disease Events in Patients with Type 2 Diabetes Mellitus.
Grewal S; Zaman N; Borgatta L; Nudy M; Foy AJ; Peterson B
Am J Cardiol; 2021 Sep; 154():48-53. PubMed ID: 34266665
[TBL] [Abstract][Full Text] [Related]
14. GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials.
Giugliano D; Maiorino MI; Bellastella G; Longo M; Chiodini P; Esposito K
Diabetes Obes Metab; 2019 Nov; 21(11):2576-2580. PubMed ID: 31373167
[TBL] [Abstract][Full Text] [Related]
15. Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials.
Al Yami MS; Alfayez OM; Alsheikh R
Heart Lung Circ; 2018 Nov; 27(11):1301-1309. PubMed ID: 29887418
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients with Type 2 Diabetes Without Baseline Metformin: A Systematic Review and Update Meta-analysis.
Lavalle-Cobo A; Masson W; Lobo M; Masson G; Molinero G
High Blood Press Cardiovasc Prev; 2021 Nov; 28(6):605-612. PubMed ID: 34705249
[TBL] [Abstract][Full Text] [Related]
17. Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis.
Peterson SC; Barry AR
Curr Diabetes Rev; 2018; 14(3):273-279. PubMed ID: 28413990
[TBL] [Abstract][Full Text] [Related]
18. Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis.
Masson W; Lavalle-Cobo A; Lobo M; Masson G; Molinero G
Eur J Prev Cardiol; 2021 Mar; 28(1):69-75. PubMed ID: 33606884
[TBL] [Abstract][Full Text] [Related]
19. GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials.
Tsapas A; Karagiannis T; Avgerinos I; Liakos A; Bekiari E
Diabetes Res Clin Pract; 2021 Jul; 177():108921. PubMed ID: 34144086
[TBL] [Abstract][Full Text] [Related]
20. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials.
Singh AK; Singh R
Diabetes Metab Syndr; 2020; 14(3):181-187. PubMed ID: 32142999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]